Copertina

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DN...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Machova Polakova, Katerina (Autore) , Zizkova, Hana (Autore) , Zuna, Jan (Autore) , Motlova, Eliska (Autore) , Hovorkova, Lenka (Autore) , Gottschalk, Andrea (Autore) , Glauche, Ingmar (Autore) , Koblihova, Jitka (Autore) , Pecherkova, Pavla (Autore) , Klamova, Hana (Autore) , Stastna Markova, Marketa (Autore) , Srbova, Dana (Autore) , Benesova, Adela (Autore) , Polivkova, Vaclava (Autore) , Jurcek, Tomas (Autore) , Zackova, Daniela (Autore) , Mayer, Jiri (Autore) , Ernst, Thomas (Autore) , Mahon, Francois X. (Autore) , Saußele, Susanne (Autore) , Röder, Ingo (Autore) , Cross, Nicholas C. P. (Autore) , Hochhaus, Andreas (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 01 August 2020
In: Leukemia
Year: 2020, Volume: 34, Fascicolo: 8, Pages: 2113-2124
ISSN:1476-5551
DOI:10.1038/s41375-020-0882-1
Accesso online:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41375-020-0882-1
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41375-020-0882-1
Testo
Note sull'autore:Katerina Machova Polakova, Hana Zizkova, Jan Zuna, Eliska Motlova, Lenka Hovorkova, Andrea Gottschalk, Ingmar Glauche, Jitka Koblihova, Pavla Pecherkova, Hana Klamova, Marketa Stastna Markova, Dana Srbova, Adela Benesova, Vaclava Polivkova, Tomas Jurcek, Daniela Zackova, Jiri Mayer, Thomas Ernst, Francois X. Mahon, Susanne Saussele, Ingo Roeder, Nicholas C.P. Cross, Andreas Hochhaus
Descrizione
Riassunto:This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n = 17) or scheduled interruption (n = 25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS = 57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS = 20% for both cohorts; red group). Thus, we propose a “traffic light” stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.
Descrizione del documento:Gesehen am 20.07.2026
Descrizione fisica:Online Resource
ISSN:1476-5551
DOI:10.1038/s41375-020-0882-1

Documenti analoghi